Anika Therapeutics reported second quarter 2026 financial results with total revenue of $32.6 million, a 16% increase year-over-year. Commercial Channel revenue reached a record $13.9 million, up 17%, while OEM Channel revenue grew 14% to $18.7 million. The company achieved net income of $3.3 million and Adjusted EBITDA of $7.1 million, marking the highest Adjusted EBITDA since 2020. Gross margin expanded to 65%. Management raised full-year 2026 guidance, projecting total revenue growth of 5% to 10% and an Adjusted EBITDA margin of 13% to 17%. The company also revised its 2027 Commercial Channel revenue growth forecast to 5% to 15%, excluding potential Hyalofast revenue due to regulatory timing uncertainty. Anika Therapeutics operates in the medical device industry, specializing in osteoarthritis pain management and orthopedic regenerative solutions.

Anika Therapeutics, Inc. entered into a Fifth Amendment to its existing revolving line of credit agreement with Bank of America, N.A. to increase its senior revolving line of credit from $50.0 million to a maximum aggregate commitment of $100.0 million. The facility matures on July 10, 2031, and interest rates are based on the Secured Overnight Financing Rate (SOFR) plus a margin of 0.25% to 1.25% depending on the leverage ratio. Anika Therapeutics, Inc. is a biotechnology company that develops and commercializes medical devices and pharmaceuticals for orthopedic and regenerative medicine.

Anika Therapeutics held its Annual Meeting of Stockholders on June 18, 2026, with 84.14% of voting power represented. Stockholders elected Gary P. Fischetti, John B. Henneman, III, and Stephen D. Griffin as Class III directors and ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026. Shareholders approved the Revised Seventh Amended 2017 Omnibus Incentive Plan, which increases the common stock reserve from 5,760,000 to 6,110,000 shares. Additionally, stockholders approved an amendment to the 2021 Employee Stock Purchase Plan, doubling the reserved shares from 200,000 to 400,000. The company operates in the biotechnology industry, focusing on regenerative medicine.